Oxford BioMedica plc Director's Share Purchase

RNS Number : 0596L
Oxford Biomedica PLC
01 July 2014
 



For immediate release

1 July 2014

 

Oxford BioMedica plc Director's Share Purchase

 

Oxford, UK - 1 July 2014: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, was informed on 30 June 2014 that one of its Directors has acquired ordinary shares of 1p each ("Ordinary Shares") as follows:

 

 

 

 

 

Interest after purchase

Director / PDMR

Title

Price per share (p)

Number of Ordinary Shares acquired on

30 June 2014

Number of Ordinary Shares

% of total

issued share capital

Paul Blake

Non-Executive Director

2.85

285,000

2,068,097

0.083%

 

The issued share capital of the Company is 2,494,584,919 1p ordinary shares.

 

-Ends-

 

For further information, please contact:

 

 

 

Oxford BioMedica plc:

John Dawson, Chief Executive Officer

Tim Watts, Chief Financial Officer

 

 

 

Tel: +44 (0)1865 783 000

 

 

 

Media Enquiries:

Mary-Jane Elliott/Emma Thompson/Matthew Neal

Consilium Strategic Communications

Tel: +44 (0)20 3709 5700

 

Notes to editors

 

Oxford BioMedica®

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline with current partners and licensees including Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb and Immune Design Corp. Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 

END

 
 

RDSGCGDRSUGBGSB